Saynor Seeks To Take Sandoz Back To Basics
Should Be Proud To Be A Generics Company
Executive Summary
In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.